『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=305410)

EID=305410EID:305410, Map:0, LastModified:2017年9月27日(水) 11:15:47, Operator:[三好 小文], Avail:TRUE, Censor:承認済, Owner:[高山 哲治], Read:継承, Write:継承, Delete:継承.
種別 (必須): 学術論文 (審査論文) [継承]
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨):
カテゴリ (推奨):
共著種別 (推奨):
学究種別 (推奨):
組織 (推奨):
著者 (必須): 1. (英) Kubo Tomohiro (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2. (英) Kawano Yutaka (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
3. (英) Himuro Nobuaki (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4. (英) Sugita Shintaro (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
5.佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
6. (英) Ishikawa Kazuma (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
7. (英) Takada Kohichi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
8. (英) Murase Kazuyuki (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
9. (英) Miyanishi Koji (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
10. (英) Sato Tsutomu (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
11. (英) Takimoto Rishu (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
12. (英) Kobune Masayoshi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
13. (英) Nobuoka Takayuki (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
14. (英) Hirata Koichi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
15.高山 哲治
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
16. (英) Mori Mitsuru (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
17. (英) Hasegawa Tadashi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
18. (英) Kato Junji (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.  (日)    [継承]
副題 (任意):
要約 (任意): (英) Preoperative chemotherapy is a promising strategy for downstaging advanced gastric cancer before radical resection, although severe adverse events can occur and clinical outcomes are often unsatisfactory. To identify predictive biomarkers of drug sensitivity, we used a well-designed functional apoptosis assay and assessed the correlations between chemosensitivity and clinical outcomes. Drug sensitivity to docetaxel, cisplatin, and 5-fluorouracil was examined in 11 gastric cancer cell lines. BCL2-homology domain 3 (BH3) profiling was performed and assessed for correlations with drug sensitivity. Immunohistochemical staining of clinical gastric cancer specimens was performed before preoperative chemotherapy, and correlations with histopathological responses and clinical outcomes were assessed. BIM (BCL2L11)-BH3 profiling results correlated with docetaxel sensitivity and BAK protein expression, whose knockdown caused docetaxel resistance. The BAK expression indexes of 69 gastric cancer specimens before preoperative chemotherapy (including docetaxel treatment) were determined by multiplying numerical values describing the degrees of BAK positivity and staining intensity observed. Patients whose specimens showed good chemotherapeutic histopathological responses had higher BAK indexes than those with poor responses. Patients with BAK index values 3 showed improved progression-free survival (HR, 2.664; 95 % CI, 1.352-5.248; P = 0.005) and overall survival (HR, 3.390; 95 % CI, 1.549-7.422; P = 0.002). BH3 profiling clearly showed that BIM expression, which depends on BAK expression, correlated with docetaxel sensitivity. BAK expression in gastric cancer is thus predictive of chemotherapeutic responses to docetaxel and clinical prognosis in patients treated with preoperative chemotherapy.  (日)    [継承]
キーワード (推奨):
発行所 (推奨):
誌名 (必須): Gastric Cancer (International Gastric Cancer Association/Japanese Gastric Cancer Association)
(pISSN: 1436-3291, eISSN: 1436-3305)

ISSN (任意): 1436-3291
ISSN: 1436-3291 (pISSN: 1436-3291, eISSN: 1436-3305)
Title: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Title(ISO): Gastric Cancer
Publisher: Springer
 (NLM Catalog  (医中誌Web  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): 19 [継承]
(必須): 3 [継承]
(必須): 827 837 [継承]
都市 (任意):
年月日 (必須): 西暦 2016年 6月 初日 (平成 28年 6月 初日) [継承]
URL (任意):
DOI (任意): 10.1007/s10120-015-0557-1    (→Scopusで検索) [継承]
PMID (任意): 26486506    (→Scopusで検索) [継承]
CRID (任意):
Scopus (任意): 1.2-s2.0-84944937274 [継承]
researchmap (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨):
備考 (任意): 1.(英) Article.PublicationTypeList.PublicationType: JOURNAL ARTICLE  (日)    [継承]
2.(英) KeywordList.Keyword: BAK  (日)    [継承]
3.(英) KeywordList.Keyword: BH3  (日)    [継承]
4.(英) KeywordList.Keyword: Docetaxel  (日)    [継承]
5.(英) KeywordList.Keyword: Gastric cancer  (日)    [継承]

標準的な表示

和文冊子 ● Tomohiro Kubo, Yutaka Kawano, Nobuaki Himuro, Shintaro Sugita, Yasushi Sato, Kazuma Ishikawa, Kohichi Takada, Kazuyuki Murase, Koji Miyanishi, Tsutomu Sato, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata, Tetsuji Takayama, Mitsuru Mori, Tadashi Hasegawa and Junji Kato : BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer., Gastric Cancer, 19, 3, 827-837, 2016.
欧文冊子 ● Tomohiro Kubo, Yutaka Kawano, Nobuaki Himuro, Shintaro Sugita, Yasushi Sato, Kazuma Ishikawa, Kohichi Takada, Kazuyuki Murase, Koji Miyanishi, Tsutomu Sato, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata, Tetsuji Takayama, Mitsuru Mori, Tadashi Hasegawa and Junji Kato : BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer., Gastric Cancer, 19, 3, 827-837, 2016.

関連情報

Number of session users = 1, LA = 0.55, Max(EID) = 468624, Max(EOID) = 1245086.